Immunovant (IMVT) COO receives new stock options and RSU grants
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Gloria Melanie reported acquisition or exercise transactions in this Form 4 filing.
Immunovant, Inc. Chief Operating Officer Gloria Melanie received new equity awards. On April 7, 2026 she was granted options to buy 121,063 shares of common stock at $24.61 per share, expiring on April 7, 2036, and 83,671 restricted stock units at no cost.
The RSUs vest 25% on April 1, 2027, with the remainder vesting in twelve substantially equal quarterly installments after that date, subject to continued service. The options vest 25% on April 1, 2027, with the balance vesting in thirty-six substantially equal monthly installments, also conditioned on continued service. After these grants, she directly owns 253,944 common shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Gloria Melanie
Role
Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 121,063 | $0.00 | -- |
| Grant/Award | Common Stock | 83,671 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 121,063 shares (Direct);
Common Stock — 253,944 shares (Direct)
Footnotes (1)
- These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.
Key Figures
RSU grant size: 83,671 units
Option grant size: 121,063 shares
Option exercise price: $24.61 per share
+3 more
6 metrics
RSU grant size
83,671 units
Restricted stock units granted April 7, 2026
Option grant size
121,063 shares
Stock options granted April 7, 2026
Option exercise price
$24.61 per share
Stock option strike price
Options expiration
April 7, 2036
Option expiration date
Shares owned after awards
253,944 shares
Common stock directly owned post-transaction
Initial vesting date
April 1, 2027
Start of RSU and option vesting schedules
Key Terms
restricted stock units ("RSUs"), 2019 Equity Incentive Plan, Stock Option (right to buy), vesting, +1 more
5 terms
restricted stock units ("RSUs") financial
"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2019 Equity Incentive Plan financial
"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan"
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
vesting financial
"The RSUs will vest as to 25% of the total shares on April 1, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"conversion_or_exercise_price": "24.6100""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
What insider transactions did Immunovant (IMVT) report for Gloria Melanie?
Immunovant reported that Chief Operating Officer Gloria Melanie received equity awards on April 7, 2026. She was granted stock options and restricted stock units as part of compensation, increasing her direct common stock holdings to 253,944 shares after these awards.
How many stock options did Immunovant (IMVT) grant to its COO?
Gloria Melanie received options for 121,063 shares of Immunovant common stock at a $24.61 exercise price. These options vest 25% on April 1, 2027 and the remaining 75% in thirty-six substantially equal monthly installments, subject to her continued service.
What restricted stock unit (RSU) grant did Immunovant (IMVT) disclose for its COO?
Immunovant granted 83,671 restricted stock units to Chief Operating Officer Gloria Melanie under its 2019 Equity Incentive Plan. Each RSU represents one common share, vesting 25% on April 1, 2027 and the remainder in twelve substantially equal quarterly installments, contingent on continued service.
When do Gloria Melanie’s Immunovant (IMVT) RSUs and options vest?
Both awards begin vesting on April 1, 2027. RSUs vest 25% then, with the balance in twelve quarterly installments. Stock options vest 25% on the same date, with the remaining 75% vesting in thirty-six substantially equal monthly installments, subject to ongoing employment.
What is the exercise price and expiration date of Immunovant (IMVT) COO’s options?
The stock options granted to Gloria Melanie have a $24.61 per share exercise price and expire on April 7, 2036. She must remain in continuous service and the options must vest before she can exercise them to acquire Immunovant common shares.